BioCentury | Jun 2, 2020

Hillhouse-backed $160M series B round to drive Genor’s first candidate to the market

Genor plans to establish a commercial team and take its first checkpoint inhibitor to market for a new indication after raising a $160 million series B round led by existing investor Hillhouse Capital. New investors...
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

Center stage at this year’s virtual ASCO meeting are a series of hot topics that demonstrate the transformative potential of a single data readout or regulatory update. Areas to watch include next-generation checkpoint targets, where...
BioCentury | May 14, 2020

With Northern Biologics deal, Boehringer adds pair of hot topics to its immuno-oncology basket

Boehringer is showing itself to be a stealthy but serious player in cutting-edge science with the latest in a series of early-stage deals that come with little notice and plant a flag in an important...
BioCentury | Apr 28, 2020

April 27 Quick Takes: Avalyn raises $35M for fibrosis therapies, plus Actym, LifeSprout, HebeCell, Compass, Immunomic

Fibrosis company Avalyn raises $35.5M series B  Seattle’s Avalyn Pharma Inc. closed a $35.5 million B round, adding to its $62 million series A in 2017. The round was led by Norwest Venture Partners with...
BioCentury | Apr 25, 2020
Targets & Mechanisms

Trends to surf for at AACR 2020

While the abstracts for this year’s virtual AACR meeting won’t be available until Monday -- and most data won’t be presented until June -- key session titles, combined with an analysis of recent trends in...
BioCentury | Apr 18, 2020
Product Development

Collaborating to clobber COVID-19

An overlapping set of collaborations is focusing the combined intellectual, logistic and economic resources of the life sciences industry, government, academia and non-profits against SARS-Cov2, the virus that causes COVID-19. The latest and broadest collaboration...
BioCentury | Apr 17, 2020
Emerging Company Profile

Rgenta: enhancing interactions between RNA and RNA-binding proteins

Rgenta launched this month with a $20 million seed round to develop compounds that enhance regulatory RNA-protein interactions. The company is disease-agnostic and using amenability to small molecule intervention to guide target selection. Co-founder, President...
BioCentury | Apr 3, 2020
Product Development

April 2 Quick Takes: Horizon takes out Curzion; plus Rgenta, Merck, Novartis-Aurobindo, Kite, Teneobio and Seattle Genetics

Horizon gains sclerosis candidate via Curzion deal  Horizon Therapeutics plc (NASDAQ:HZNP) acquired privately held Curzion Pharmaceuticals Inc., giving it LPAR1 antagonist HZN-825 (CZN001). Curzion’s shareholders received $45 million up front and are eligible for milestones...
BioCentury | Mar 27, 2020
Product Development

Pharmas to share assets in COVID-19 consortium led by Narasimhan, Gates

Global alliances among public, private and non-profit entities to counter COVID-19 continue to gather steam, with one of the latest alliances comprising over a dozen life sciences companies and the Gates Foundation. Novartis AG (NYSE:NVS;...
BioCentury | Mar 23, 2020
Product Development

March 23 Quick Takes: Venclexta combo hits in AML; plus Jardiance rebuffed, Zolgensma approved in Japan and Zealand-Boehringer

Venclexta combo shows survival benefit in AML  Partners Roche (SIX:ROG; OTCQX:RHHBY) and AbbVie Inc. (NYSE:ABBV) said Venclexta venetoclax plus azacitidine significantly improved overall survival and composite complete remission rate among acute myelogenous leukemia (AML) patients...
Items per page:
1 - 10 of 2349